Indian scientists pave way for developing new therapy for tongue cancer

However, its ability to prevent cancer is significantly compromised, if it mutates. More importantly, recent studies have reported that some specific and common mutated p53 forms even activate cancer growth.

In a new study, scientists at CDFD have identified rare p53 mutant forms unique to Indian tongue cancer and the likely means by which these mutant p53 cause cancer. For this, they collected tongue cancer samples from post-surgery patients and screened them for modifications in a gene called TP53. The gene is a sequence of nucleotides (building blocks) in the DNA that code for the production of the p53 protein.

Further, by using state of the art technologies, they identified target genes of the mutant p53 protein. Of these, a gene called SMARCD1 was the most prominent. SMARCD1 encodes a protein that along with several other proteins constitutes a multi-protein complex involved in changing the structure of DNA enabling the production of proteins from genes. Surprisingly, the scientists found that SMARCD1 was an exclusive target of mutations observed in Indian tongue cancer patients. Further studies showed the ability of SMARCD1 to increase cancerous features in tongue cancer cells.

Notably, this is the first time that SMARCD1 has been shown to be a possible driver of any form of cancer. The leader of the study team, Dr M.D. Bashyam of the Laboratory of Molecular Oncology at the Centre said, "The observations made in this study assume significance since they reveal a new and probable mechanism by which mutant p53 proteins encourage cancer development. The results of the study can be employed to develop therapies to treat tongue cancer, a common debilitating cancer in India".